Peptide-peptidase inhibitor conjugates and methods of using same
AssigneesAstraZeneca Pharmaceuticals LP, Amylin Pharmaceuticals, Inc.
InventorsSoumitra S. GHOSH, Josue ALFARO-LOPEZ, Lawrence J. D'Souza, Odile Esther LEVY, Qing LIN, Christopher J. SOARES
Life of this patent
Estimating the term…
Abstract
Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.
Claims16
A peptide-peptidase inhibitor conjugate comprising a peptide covalently linked to a peptidase inhibitor.
The conjugate according to claim 10, wherein the GIP hybrid comprises a GIP peptide linked to an exendin peptide or an amylin peptide.
The conjugate according to claim 11, wherein the GIP hybrid comprises the sequence as set forth in any one of SEQ ID NOs:
- 1, 291, 292, or 233-246.
Dependencies are inferred from the claim text.